-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54

Benzinga·08/12/2026 12:05:09
Listen to the news
BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.